NeuroOne Medical Technologies Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda NeuroOne Medical Technologies için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.4%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Dec 16

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Jul 25

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Apr 11

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Sep 15

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

Aug 03

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Jun 02

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

Dec 18

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

Nov 19

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Sep 04

We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

May 27

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak NeuroOne Medical Technologies yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:NMTC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	4	-12	-11	-11	N/A
3/31/2024	4	-13	-12	-12	N/A
12/31/2023	3	-13	-14	-13	N/A
9/30/2023	3	-12	-13	-13	N/A
6/30/2023	5	-10	-9	-9	N/A
3/31/2023	4	-9	-9	-9	N/A
12/31/2022	4	-9	-9	-8	N/A
9/30/2022	2	-10	-8	-8	N/A
6/30/2022	0	-11	-11	-11	N/A
3/31/2022	0	-11	-10	-10	N/A
12/31/2021	0	-11	-10	-9	N/A
9/30/2021	0	-10	-9	-9	N/A
6/30/2021	2	-8	-6	-6	N/A
3/31/2021	2	-12	-5	-5	N/A
12/31/2020	2	-11	-4	-4	N/A
9/30/2020	2	-14	-4	-3	N/A
6/30/2020	N/A	-14	-5	-5	N/A
3/31/2020	N/A	-9	-5	-5	N/A
12/31/2019	N/A	-10	-6	-6	N/A
9/30/2019	N/A	-7	-6	-5	N/A
6/30/2019	N/A	-8	-5	-5	N/A
3/31/2019	N/A	-7	-4	-4	N/A
12/31/2018	N/A	-6	-3	-3	N/A
9/30/2018	N/A	-7	-3	-3	N/A
6/30/2018	N/A	-6	-3	-2	N/A
3/31/2018	N/A	-6	N/A	-2	N/A
12/31/2017	N/A	-5	N/A	-2	N/A
9/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NMTC 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.5% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: NMTC 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: NMTC şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: NMTC şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: NMTC şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NMTC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

NeuroOne Medical Technologies Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 25% to US$2.00

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Consensus revenue estimates increase by 13%, EPS downgraded

Consensus revenue estimates increase by 13%

Consensus revenue estimates decrease by 41%, EPS upgraded

Recent updates

Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.20 loss in 3Q 2023)

NeuroOne Medical Technologies Corporation to Report Q3, 2024 Results on Aug 14, 2024

NeuroOne Medical Technologies Corporation announced that it has received $2.650001 million in funding

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Insufficient new directors

NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System

Neuroone Medical Technologies Corporation Receives Approval of ICD-10 Procedure Code for sEEG RF Ablation

Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.21 loss in 2Q 2023)

NeuroOne Medical Technologies Corporation to Report Q2, 2024 Results on May 14, 2024

Price target decreased by 25% to US$2.00

NeuroOne Medical Technologies Corporation Initiates Limited Commercial Launch of OneRF Ablation System

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

NeuroOne Medical Technologies Corporation to Report Q1, 2024 Results on Feb 13, 2024

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024

Chief Operating Officer recently bought US$105k worth of stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroOne Medical Technologies Corporation Receives FDA 510(K) Clearance to Market its OneRF(TM) Ablation System

NeuroOne Medical Technologies Corporation to Report Q4, 2023 Results on Dec 14, 2023

NeuroOne Medical Technologies Corporation Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

NeuroOne Medical Technologies Corporation Appoints Christopher R. Volker as Chief Operating Officer

NeuroOne Medical Technologies Corporation Provides Progress Update on FDA 510(k) Submission for OneRF™? Ablation System

Chief Financial Officer recently bought US$50k worth of stock

Consensus revenue estimates increase by 13%, EPS downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation to Report Q3, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

NeuroOne Medical Technologies Corporation Submits 510(K) Application to FDA for OneRF™ Ablation System

NeuroOne Medical Technologies Corporation Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

Consensus revenue estimates increase by 13%

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2022)

NeuroOne Medical Technologies Corporation to Report Q2, 2023 Results on May 11, 2023

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Consensus revenue estimates decrease by 41%, EPS upgraded

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

NeuroOne Medical Technologies Corporation to Report Q1, 2023 Results on Feb 14, 2023

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 16, 2023

Consensus revenue estimates increase by 154%

NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Successfully Completes Feasibility Study with its OneRF Ablation System

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Receives U.S. Food and Drug Administration 510(K) Clearance to Market Its Evo sEEG System for Less Than 30 Day Use

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation Submits Special 510(k) to FDA for Evo sEEG Electrode

Consensus estimates of losses per share improve by 13%

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

NeuroOne Announces First Clinical Case Using Evo sEEG Electrode

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

NeuroOne Medical Technologies Corporation Provides Evo's EEG Update

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.21 loss in 2Q 2021)

NeuroOne Medical Technologies Corporation to Report Q2, 2022 Results on May 12, 2022

NeuroOne Medical Technologies Corporation, Annual General Meeting, May 31, 2022

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Releases Successful Completion of Long-Term Stimulation Tests for Its Novel Thin Film Platform Electrode Technology

First quarter 2022 earnings: EPS misses analyst expectations

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for Its Novel Thin Film Platform Electrode Technology

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

NeuroOne® Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo sEEG Electrode

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Insider recently sold US$80k worth of stock